Hepatitis C Drug Raises Cure Rate in Late Trial
June 7, 2010
A Phase III trial of Vertex Pharmaceuticals' experimental hepatitis C virus drug telepravir boosted cure rates of infected patients taking standard treatment, the firm recently announced. With standard therapy and telepravir, 75 percent had a sustained virological response, compared with 44 percent of patients taking standard therapy only. Telepravir works by blocking protease enzymes made by HCV.
Of those who took the longer 12-week course of telepravir, 75 percent had no detectable virus in their blood 24 weeks after completing treatment, which is seen as a cure. The eight-week telepravir group had a 69 percent cure rate.
New York Times
05.26.2010; Andrew Pollack
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)